青少年特发性关节炎相关葡萄膜炎抗炎治疗循证指南更新
德国多学科团队制定青少年特发性关节炎相关葡萄膜炎(JIAU)抗炎治疗循证指南,基于系统文献分析及共识会议形成推荐。指南提出按葡萄膜炎严重程度分层治疗:局部糖皮质激素无效时启用甲氨蝶呤,未达静止加用TNFα抗体(优选阿达木单抗),失败可换其他生物制剂,减药前需葡萄膜炎静止≥2年。
要点
- 局部糖皮质激素(≤2次/日)无效的JIAU应启用甲氨蝶呤。
- 甲氨蝶呤未达静止加用TNFα抗体,优选阿达木单抗。
- TNFα抗体失败可换托珠单抗、阿巴西普或利妥昔单抗。
核心结论
- JIAU抗炎治疗应按葡萄膜炎严重程度分层,局部激素无效时依次启用甲氨蝶呤、TNFα抗体(优选阿达木单抗)及其他生物制剂。
研究设计与样本
- 由德国眼科学会、儿科风湿病学会、眼科医师专业协会、德国风湿病学会及家长组代表参与制定,由德国科学医学会协会主持。
- 系统检索MEDLINE文献,对证据和推荐分级,经共识会议(名义群体法)讨论治疗算法和最终声明,再经德尔菲程序由所有参与者修订。
主要发现
- 共识推荐:对低剂量(≤2次/日)局部糖皮质激素无反应的葡萄膜炎应启用甲氨蝶呤。
- 若未达到葡萄膜炎静止,应使用TNFα抗体(优选阿达木单抗)。
- 对于非常严重活动性葡萄膜炎伴视力恶化者,可考虑全身糖皮质激素桥接治疗直至DMARD起效。
- 若TNFα抗体无效或失效,应选择另一种生物制剂(托珠单抗、阿巴西普或利妥昔单抗)。
- DMARD减量前需葡萄膜炎静止≥2年。
关键数值与推荐
- 局部糖皮质激素低剂量定义为≤2次/日。
- DMARD减药前葡萄膜炎静止时间应≥2年。
临床怎么用
- 依据葡萄膜炎严重程度分层,局部激素无效时及时启用甲氨蝶呤。
- 甲氨蝶呤未达静止加用TNFα抗体(优选阿达木单抗)。
- TNFα抗体失败后换用托珠单抗、阿巴西普或利妥昔单抗。
- 减量DMARD前确保葡萄膜炎已静止≥2年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the development of complications and visual loss. Topical corticosteroids are the first line therapy, and disease modifying anti-rheumatic drugs (DMARDs) are commonly used. However, treatment has not been standardized. METHODS: Interdisciplinary guideline were developed with representatives from the German Ophthalmological Society, Society for Paediatric Rheumatology, Professional Association of Ophthalmologists, German Society for Rheumatology, parents' group, moderated by the Association of the Scientific Medical Societies in Germany. A systematic literature analysis in MEDLINE was performed, evidence and recommendations were graded, an algorithm for anti-inflammatory treatment and final statements were discussed in a consensus meeting (Nominal Group Technique), a preliminary draft was fine-tuned and discussed thereafter by all participants (Delphi procedure). RESULTS: Consensus was reached on recommendations, including a standardized treatment strategy according to uveitis severity in the individual patient. Thus, methotrexate shall be introduced for uveitis not responding to low-dose (≤ 2 applications/day) topical corticosteroids, and a TNFalpha antibody (preferably adalimumab) used, if uveitis inactivity is not achieved. In very severe active uveitis with uveitis-related deterioration of vision, systemic corticosteroids should be considered for bridging until DMARDs take effect. If TNFalpha antibodies fail to take effect or lose effect, another biological should be selected (tocilizumab, abatacept or rituximab). De-escalation of DMARDs should be preceded by a period of ≥ 2 years of uveitis inactivity. CONCLUSIONS: An interdisciplinary, evidence-based treatment guideline for JIAU is presented.
引用
- Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2018. PMID: 30595409. doi:10.1016/j.semarthrit.2018.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。